2 active not recruiting, 2 completed, 1 approved for marketing, 1 not yet recruiting. 4 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Curium US LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms Somatostatin Analogue(s) - Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm | Phase 3 | Not yet recruiting | Washington University School of Medicine | 240 | 2026-11-30 | 2026-10-19 |
| Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE Brain Imaging with [Cu64]DOTATATE, Radio-guided Surgery With Neoprobe Utilization - Meningioma | Phase 4 | Recruiting | Weill Medical College of Cornell University | 20 | 2024-09-11 | 2026-02-27 |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | Curium US LLC | 235 | 2024-04-01 | 2026-02-18 |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Active not recruiting | Curium US LLC | 439 | 2024-04-01 | 2026-10-27 |
| Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer 64Cu-PSMA I&T - Metastasis From Malignant Tumor of Prostate (Disorder) | Phase 2 | Completed | Curium US LLC | 26 | 2022-12-05 | 2025-01-24 |
| 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer 177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide - Metastasis From Malignant Tumor of Prostate | Phase 3 | Active not recruiting | Curium US LLC | 439 | 2022-02-14 | 2026-09-04 |
| Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs) Copper Cu 64 Dotatate - Neuroendocrine Tumors | Approved for marketing | Curium US LLC | 2020-10-09 |
Prostatic Neoplasms (4) · Neuroendocrine Tumors (2) · Carcinoid Tumor (1) · Meningioma (1)
Neuroimaging (1) · Prednisone (1) · abiraterone (1) · enzalutamide (1)
United States (6) · France (1) · Italy (1) · Spain (1)